- Persistent respiratory symptoms: Chronic cough, breathlessness, chest discomfort or unexplained haemoptysis.
- Indeterminate imaging findings: Lung nodules, masses or abnormal scans requiring further clinical clarification.
- High-risk individuals: Smoking history, occupational exposure or strong family history of lung cancer.
- Unexplained systemic features: Weight loss, fatigue or reduced exercise tolerance without clear diagnosis.
- Diagnostic support pathway: Additional investigation where lung cancer is suspected and further assessment is required.
- Monitoring clinical suspicion: Ongoing concern despite inconclusive conventional testing.
Overview
Trublood® - Lung Cancer analyses circulating tumour cells and tumour-derived nucleic material detectable in peripheral blood. These biomarkers may reflect tumour activity and biological characteristics relevant to diagnostic assessment.
Investigation of suspected lung malignancy typically involves imaging, respiratory evaluation and tissue sampling. When findings are indeterminate or invasive biopsy is not feasible, blood-based tumour biomarker analysis may provide additional support in clarifying malignancy risk.
Results are interpreted alongside symptom history, radiological findings, smoking exposure and specialist clinical assessment. Integrating circulating tumour biomarker findings into the wider diagnostic pathway may help guide decisions around further investigation or referral.
Practical
Specimen
Whole blood
Container
- 1 x 2 ml SST tube (yellow colour cap)
- 2 x EDTA tubes (purple colour cap)
- 1 x 8 ml DCG tube
Volume
17 mL
Patient preparation
The patient must not have received any form of cancer therapy (radiation / chemo-therapy / surgery / endocrine therapy etc.) at least 15 days prior to collection of sample.
The patient must not have received oral or IV corticosteroids at least 15 days prior to collection of sample.
Patient has no current febrile or any other acute inflammatory illness.
Patient does not have acute exacerbation or flare-up of an inflammatory condition requiring escalation in medical therapy at least 5 days prior to collection of sample.
Patient has not received blood transfusion / PET-CT / CT scan at least 5 days prior to collection of sample.
Patient is not positive for HIV / HBV / HCV.